Although outcomes have improved for patients with multiple myeloma (MM), this disease remains a challenging condition, placing a considerable burden on patients and requiring judicious selection of upfront and sequential therapy on the part of clinicians. A growing body of evidence and clinical experience from both the European Union and the United States now supports the rapid integration of CD38 antibody quadruplet regimens in newly diagnosed MM (NDMM)–a development with implications for first-line and successive lines of therapy.

In this CME-certified PeerView Live “Clinical Consults” symposium held during the 2024 COMy Congress in Paris, France, leading MM specialists will use a series of conversational, case-based discussions to share their clinical experiences and provide valuable insights on crafting proactive upfront treatment with antibody-based quadruplets while offering guidance on dosing, scheduling, and safety considerations in transplant-eligible and ineligible patients. Don’t forget to sign up early and join us at COMy 2024 for this exciting event! Sign up today: PeerView.com/ParisMM-Live.

This activity is supported by an educational grant from Sanofi.